Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder
1 other identifier
interventional
90
1 country
1
Brief Summary
Pancreatic cancer is a difficult to treat disease, mainly due to the fact that diagnosis is made usually in the late stage of this condition. One of the treatment methods of pain accompanying this neoplasm is thoracoscopic splanchnicectomy. It has been shown that it is a safe procedure with a small percentage of complications, nevertheless it is often use as the last stage in pain management what significantly decreases its effectiveness. The aim of this study is to determinate the effect of invasive pain treatment (splanchnicectomy) in patients with advanced pancreatic cancer on subjective pain perception at rest, in movement and after meals (measured with the BPI, QLQ- C30 and FACIT questionnaires), and suffering (measured with PRISM projection test), the use of painkillers during the disease and patients' overall survival. Moreover the investigators want to check if early performance of splanchnicectomy (on lower steps of analgesic ladder WHO) is combined with better therapeutic effect of this treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable pancreatic-cancer
Started Sep 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2014
CompletedFirst Submitted
Initial submission to the registry
January 2, 2015
CompletedFirst Posted
Study publicly available on registry
April 23, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2017
CompletedApril 23, 2015
April 1, 2015
2.7 years
January 2, 2015
April 18, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline pain intensity at 1 year (BPI questionnaires)
one year
Secondary Outcomes (1)
Quality of life and pain intensity measurement (measured with the QLQ- C30, FACIT and BPI questionnaires)
From date of randomization until the date of death from any cause,assessed up to 100 months
Study Arms (2)
Surgical treatment
ACTIVE COMPARATORPatients from the first group will undergo thoracoscopic splanchnicectomy. The surgery will be performed in general anaesthesia, with tracheal intubation in prone position. The greater splanchnic nerve will be identified at its origin in sympathetic trunk, dissected together with all collaterals all the way down to the diaphragm and excised. Additional splanchnic nerves (smaller, minimus) will be incised or excised if connected to the greater splanchnic nerve. Single sutures will be applied to the skin. Then the procedure will be repeated on the contralateral side.
Conservative Treatment
NO INTERVENTIONPatients from the second group will be offered best available conservative pain treatment. The list of medication on stage 1 will include: paracetamol, ibuprofen, diclofenac. On stage 2: stage 1 + codeine and tramadol. On stage 3: stage 2 + morphine, fentanyl, oxycodone, pethidine. Oral and transcutaneous routes will be preferred to intravenous, intramuscular and subcutaneous. A need for elevation to the next step of analgesic ladder will be considered when the pain will be stronger than 6 points in Numeric Rating Scale (NRS) and will be present for more than 5 days.
Interventions
Eligibility Criteria
You may qualify if:
- Patients diagnosed with pancreatic cancer
- Age over 18 years
- Signed informed consent to participate in the study
You may not qualify if:
- Age under 18 years
- Intellectual inability to fill the questionnaires
- Co-occurrence of a disease in which significant chronic pain exists, which was recognized before the onset of pancreatic cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk.
Gdansk, Poland
Related Publications (1)
Dobosz L, Stefaniak T, Dobrzycka M, Wieczorek J, Franczak P, Ptaszynska D, Zasada K, Kanyion P. Invasive treatment of pain associated with pancreatic cancer on different levels of WHO analgesic ladder. BMC Surg. 2016 Apr 18;16:20. doi: 10.1186/s12893-016-0136-3.
PMID: 27090728DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
January 2, 2015
First Posted
April 23, 2015
Study Start
September 1, 2014
Primary Completion
May 1, 2017
Study Completion
September 1, 2017
Last Updated
April 23, 2015
Record last verified: 2015-04